[go: up one dir, main page]

MA30089B1 - (arylsulfonyl)-pyrasolopiperidines - Google Patents

(arylsulfonyl)-pyrasolopiperidines

Info

Publication number
MA30089B1
MA30089B1 MA31080A MA31080A MA30089B1 MA 30089 B1 MA30089 B1 MA 30089B1 MA 31080 A MA31080 A MA 31080A MA 31080 A MA31080 A MA 31080A MA 30089 B1 MA30089 B1 MA 30089B1
Authority
MA
Morocco
Prior art keywords
formula
compounds
pyrasolopiperidines
arylsulfonyl
alzheimer
Prior art date
Application number
MA31080A
Other languages
English (en)
Inventor
Albert W Garofalo
Jacek J Jagodzinski
Andrei W Konradi
Christopher M Semko
Jenifer L Smith
Ying-Zi Xu
Xiaocong Michael Ye
Original Assignee
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc
Publication of MA30089B1 publication Critical patent/MA30089B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne des composés de sulfonamido N-cycliques de formule I dans laquelle A, B, R1, R1a, R2, R2a, R3 et R3a sont tels que décrits dans le mémoire descriptif. Les composés de formule I sont utiles pour le traitement ou la prévention de troubles de la cognition tels que la maladie d'Alzheimer. L'invention concerne également des compositions pharmaceutiques qui comprennent des composés de formule I, des procédés de préparation de composés de formule I et de procédés de traitement de troubles de la cognition tels que la maladie d'Alzheimer.
MA31080A 2005-12-01 2008-06-26 (arylsulfonyl)-pyrasolopiperidines MA30089B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74136605P 2005-12-01 2005-12-01

Publications (1)

Publication Number Publication Date
MA30089B1 true MA30089B1 (fr) 2008-12-01

Family

ID=38092841

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31080A MA30089B1 (fr) 2005-12-01 2008-06-26 (arylsulfonyl)-pyrasolopiperidines

Country Status (18)

Country Link
US (2) US7732609B2 (fr)
EP (1) EP1957458A2 (fr)
JP (1) JP2009518301A (fr)
KR (1) KR20080073359A (fr)
CN (1) CN101370776A (fr)
AR (1) AR057959A1 (fr)
AU (1) AU2006320423B2 (fr)
BR (1) BRPI0619633A2 (fr)
CA (1) CA2632227A1 (fr)
EA (1) EA014906B1 (fr)
EC (1) ECSP088593A (fr)
IL (1) IL190608A0 (fr)
MA (1) MA30089B1 (fr)
MY (1) MY149422A (fr)
NZ (1) NZ568109A (fr)
PE (1) PE20071090A1 (fr)
TW (1) TW200736255A (fr)
WO (1) WO2007064914A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007138072A2 (fr) * 2006-05-31 2007-12-06 Galapagos N.V. Composés de triazolopyrazine utilisés dans le traitement des maladies dégénératives et inflammatoires
ES2373253T3 (es) * 2007-05-25 2012-02-01 Elan Pharmaceuticals Inc. Pirazolopirrolidinos como inhibidores de gamma secretasa.
EP2271625B1 (fr) 2008-04-01 2012-09-12 Abbott GmbH & Co. KG Tétrahydroisoquinoléines, compositions pharmaceutiques les contenant et leur utilisation en thérapie
AR075442A1 (es) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
TW201038569A (en) * 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
JP2012521993A (ja) * 2009-03-25 2012-09-20 エラン ファーマシューティカルズ，インコーポレイテッド 縮合三環式スルホンアミドの製造プロセス
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2013020930A1 (fr) 2011-08-05 2013-02-14 Abbott Gmbh & Co. Kg Dérivés d'aminochromane, d'aminothiochromane et d'amino-1,2,3,4-tétrahydroquinoléine, compositions pharmaceutiques contenant ceux-ci et leur utilisation thérapeutique
US8846741B2 (en) 2011-11-18 2014-09-30 Abbvie Inc. N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
CA2924689A1 (fr) 2013-10-17 2015-04-23 AbbVie Deutschland GmbH & Co. KG Derives d'aminochromane, d'aminothiochromane et d'amino-1,2,3,4-tetrahydroquinoleine, compositions pharmaceutiques contenant ceux-ci et leur utilisation therapeutique
CN105764895A (zh) 2013-10-17 2016-07-13 艾伯维德国有限责任两合公司 氨基四氢化萘及氨基二氢化茚衍生物，包含其的药物组合物及其在治疗中的用途
CN104059063A (zh) * 2014-04-03 2014-09-24 丽水绿氟科技有限公司 7,7-二氟-4,5,6,7-四氢吡唑并[4,3-c]吡啶及其衍生物的制备方法
CN112074505B (zh) 2018-03-08 2024-04-05 因赛特公司 作为PI3K-γ抑制剂的氨基吡嗪二醇化合物
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996012720A1 (fr) * 1994-10-20 1996-05-02 Pfizer Inc. Tetrahydropyrazolopyridines bicycliques et leur emploi comme medicaments
DE60143041D1 (de) * 2000-08-10 2010-10-21 Pfizer Italia Srl Bizyklische pyrazole wirksam als kinase inhibitoren, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
MXPA04003330A (es) * 2001-10-09 2004-07-08 Kyorin Seiyaku Kk 4-(2-furoil) aminopiperidinas novedosas, compuestos intermedios en la sintesis de las mismas, proceso para producirlas y su uso medicinal.
AU2003292724A1 (en) 2002-12-27 2004-07-29 Japan Tobacco Inc. Fused n-containing heterocyclic compounds and medicinal use thereof
EP1758884A2 (fr) * 2004-05-20 2007-03-07 Elan Pharmaceuticals, Inc. Inhibiteurs sulfonamido n-cycliques de gamma-secretase
DE602005026037D1 (de) * 2004-10-27 2011-03-03 Janssen Pharmaceutica Nv Tetrahydro pyridinyl pyrazole cannabinoid modulatoren
DE102005002500A1 (de) * 2005-01-19 2006-07-27 Sanofi-Aventis Deutschland Gmbh Tetrahydrofuranderivate als Inhibitoren von Matrix-Metalloproteinasen
JP2008534496A (ja) * 2005-03-22 2008-08-28 アストラゼネカ・アクチエボラーグ ＣＢ１’受容体リガンドとしての新規なテトラヒドロ−１Ｈ−ピリド［４，３−ｂ］インドール誘導体
DE102005016170A1 (de) * 2005-04-07 2006-10-12 Grünenthal GmbH 4,5,6,7- Tetrahydro-isoxazolo(4,5c)pyridin-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
WO2007024651A2 (fr) 2005-08-19 2007-03-01 Elan Pharmaceuticals, Inc. Inhibiteurs sulfonamido n-bicycliques pontes de gamma-secretase

Also Published As

Publication number Publication date
EP1957458A2 (fr) 2008-08-20
CA2632227A1 (fr) 2007-06-07
US20100267747A1 (en) 2010-10-21
CN101370776A (zh) 2009-02-18
MY149422A (en) 2013-08-30
AU2006320423A1 (en) 2007-06-07
US20070155753A1 (en) 2007-07-05
PE20071090A1 (es) 2007-10-24
JP2009518301A (ja) 2009-05-07
NZ568109A (en) 2011-07-29
AU2006320423B2 (en) 2012-06-21
ECSP088593A (es) 2008-08-29
WO2007064914A8 (fr) 2008-05-15
TW200736255A (en) 2007-10-01
WO2007064914A2 (fr) 2007-06-07
KR20080073359A (ko) 2008-08-08
WO2007064914A3 (fr) 2007-12-27
US7732609B2 (en) 2010-06-08
EA014906B1 (ru) 2011-02-28
BRPI0619633A2 (pt) 2011-10-04
IL190608A0 (en) 2008-11-03
EA200801481A1 (ru) 2009-02-27
AR057959A1 (es) 2007-12-26

Similar Documents

Publication Publication Date Title
MA30089B1 (fr) (arylsulfonyl)-pyrasolopiperidines
MA27347A1 (fr) Inhibiteurs de protease du vih, compositions les contenant, leurs utilisations pharmaceutiques et matieres pour leur synthese
TNSN08445A1 (fr) Derives de triazolopyrazine utiles comme agent anticancereux
MA31373B1 (fr) Composes amino-heterocycliques
TNSN04246A1 (fr) Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation
MA27568A1 (fr) Derives de pyrrolopyrimidine
TN2010000175A1 (fr) Piperidino-dihydrothienopyrimidines substituees
MA27774A1 (fr) Inhibiteurs de phosphatidylinositol 3-kinase
MA27097A1 (fr) Aza-arylpiperazines
MA29411B1 (fr) 1h-quinazoline -2,4-diones et leur utilisation en tant que ligands du recepteur ampa
MA29772B1 (fr) Benzimidazoles substitues et procedes de preparation
MA30911B1 (fr) Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine
MA30696B1 (fr) Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique
MA30532B1 (fr) Sulfonamides tricycliques condenses inhibiteurs de gamma-secretase
MA29692B1 (fr) Derives de la xanthine en tant qu'agonistes selectifs du hm74a
MA31754B1 (fr) Cis-imidazolines chirales
MA27883A1 (fr) Derives de pyrido [2,1-a] isoquinoline utilises comme inhibiteurs de dpp-iv
MA26723A1 (fr) Acides oxamiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
EP1562897A4 (fr) Inhibiteurs de beta-secretase phenylcarboxamide utilises dans le traitement de la maladie d'alzheimer
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
TNSN07476A1 (fr) Derives de n-(pyridine -2- yl) - sulfonamide
TNSN98084A1 (fr) Derives de macrolides substitues en position c-4
MA31766B1 (fr) Composés organiques
MA24729A1 (fr) Macrolides nouveaux.
TNSN05073A1 (fr) Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase